Ao Danyi, He Xuemei, Hong Weiqi, Wei Xiawei
Laboratory of Aging Research and Cancer Drug Target, State Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics West China Hospital, Sichuan University Chengdu Sichuan China.
MedComm (2020). 2023 Mar 15;4(2):e239. doi: 10.1002/mco2.239. eCollection 2023 Apr.
As the fifth variant of concern of the SARS-CoV-2 virus, the Omicron variant (B.1.1.529) has quickly become the dominant type among the previous circulating variants worldwide. During the Omicron wave, several subvariants have emerged, with some exhibiting greater infectivity and immune evasion, accounting for their fast spread across many countries. Recently, two Omicron subvariants, BQ.1 and XBB lineages, including BQ.1.1, XBB.1, and XBB.1.5, have become a global public health issue given their ability to escape from therapeutic monoclonal antibodies and herd immunity induced by prior coronavirus disease 2019 (COVID-19) vaccines, boosters, and infection. In this respect, XBB.1.5, which has been established to harbor a rare mutation F486P, demonstrates superior transmissibility and immune escape ability compared to other subvariants and has emerged as the dominant strain in several countries. This review provides a comprehensive overview of the epidemiological features, spike mutations, and immune evasion of BQ.1 and XBB lineages. We expounded on the mechanisms underlying mutations and immune escape from neutralizing antibodies from vaccinated or convalescent COVID-19 individuals and therapeutic monoclonal antibodies (mAbs) and proposed strategies for prevention against BQ.1 and XBB sublineages.
作为严重急性呼吸综合征冠状病毒2(SARS-CoV-2)病毒的第五种受关注变体,奥密克戎变体(B.1.1.529)迅速成为全球此前流行变体中的主要类型。在奥密克戎毒株流行期间,出现了几个亚变体,其中一些表现出更强的传染性和免疫逃逸能力,这解释了它们在许多国家迅速传播的原因。最近,两种奥密克戎亚变体,即BQ.1和XBB谱系,包括BQ.1.1、XBB.1和XBB.1.5,因其能够逃避治疗性单克隆抗体以及先前的2019冠状病毒病(COVID-19)疫苗、加强针和感染所诱导的群体免疫,已成为一个全球公共卫生问题。在这方面,已确定携带罕见突变F486P的XBB.1.5与其他亚变体相比,具有更强的传播性和免疫逃逸能力,并已在几个国家成为优势毒株。本综述全面概述了BQ.1和XBB谱系的流行病学特征、刺突突变和免疫逃逸情况。我们阐述了接种疫苗或感染康复的COVID-19个体以及治疗性单克隆抗体(mAbs)中突变和对中和抗体免疫逃逸的潜在机制,并提出了针对BQ.1和XBB亚谱系的预防策略。